Moxonidine in metabolic syndrome

Е.А. Чубенко^{1, 2}, О.Д. Беляева¹, Е.А. Баженова¹, Т.Л. Каронова¹, С.Е. Нифонтов1, О.А. Беркович¹, Е.и. Баранова^{1, 2}

Authors: Е.А. chubenko1, 2, O.D. Belyaeva1, E.A. Bazhenova1, T.L. Karonova1, S.E. Nifontov1, O.A. Berkovich1, E.i. Baranova1, 2

Place: St Petersburg, Russia

Institution: 1 The First Pavlov St Petersburg State Medical University
2 Federal Almazov Medical Research Center

Abstract:

Objective. Imidazoline receptor agonist moxonidine besides antihypertensive effect can increase insulin sensitivity, reduce leptin level, and improve lipid metabolism. However, the efficacy, tolerability and pleiotropic effects of moxonidine in postmenopausal women with essential hypertension (EH) and metabolic syndrome (MS) are not well established, and it was the purpose of this study. Design and methods. Forty-two postmenopausal women with EH and MS (mean age — 52,5 ± 0,4 years) were enrolled. Moxonidine therapy (400-600 mkg/ daily) lasted for 12 weeks. Waist (WC) and hip (HC) circumferences, WC/HC ratio, body mass index (BMI), insulin, leptin level, glucose, blood serum lipid profile, index of insulin resistance (HOMA-IR) and index of functional activity of pancreatic beta cells (HOMA-FB), echocardiography, intima-media thickness of common carotid arteries. Results. Moxonidine therapy was associated with decrease, body weight and BMI decrease, high-density lipoprotein cholesterol and HOMA-FB index increase. Left atrium diameter and volume decreased, left ventricular diastolic function improved. Conclusions. Moxonidine is an effective antihypertensive drug for the treatment of postmenopausal hypertensive women with MS, which improves some metabolic, hemodynamic parameters and leads to the decrease of the left atrium volume and diameter.  

Keywords: moxonidine, insulin resistance, leptin, metabolic syndrome, heart remodeling

482.32 KB 3